Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
T. Link, M. Reinisch, M. Just, M. Untch, N. Filmann, O. Stötzer, C. Denkert, V. Bjelic-Radisic, P. Wimberger, M. Thill, K. Rhiem, J. Huober, C. Solbach, C. Hanusch, K. Engels, P.A. Fasching, A. Schneeweiss, V. Nekljudova, J. Holtschmidt, J.-U. Blohmer, S. Loibl · 2025
Read Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX) by T. Link, M. Reinisch, M. Just, M. Untch, N. Filmann, O. Stötzer, C. Denkert, V. Bjelic-Radisic, P. Wimberger, M. Thill, K. Rhiem, J. Huober, C. Solbach, C. Hanusch, K. Engels, P.A. Fasching, A. Schneeweiss, V. Nekljudova, J. Holtschmidt, J.-U. Blohmer, S. Loibl (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12702335.txt.
Description
BackgroundIn the GeparX trial (NCT02682693), neoadjuvant denosumab, in addition to either weekly or days 1 and 8 (d1,8) q22 nab-paclitaxel (nPac)-based chemotherapy, did not improve the pathological complete response (pCR) rate in early high-risk breast cancer patients, while the concomitantly applied weekly nPac regimen resulted in a significantly higher pCR rate compared with the interrupted regimen.
Catalog record
| CREATOR | T. Link, M. Reinisch, M. Just, M. Untch, N. Filmann, O. Stötzer, C. Denkert, V. Bjelic-Radisic, P. Wimberger, M. Thill, K. Rhiem, J. Huober, C. Solbach, C. Hanusch, K. Engels, P.A. Fasching, A. Schneeweiss, V. Nekljudova, J. Holtschmidt, J.-U. Blohmer, S. Loibl |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |